drugset / Trial / NCT00699283

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

NCT00699283

Phase 3 Terminated 62 enrolled UCB Pharma
RandomizedParallel-groupTriple-blindTreatment

Summary

Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of BRV in the conversion of partial onset seizure patients from combination treatment to monotherapy.

Timeline

Start
2008-08
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 50 mg
Subject Brivaracetam Small molecule 100 mg

Indications